At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 4,891 enrolled
Drug / intervention
Remdesivir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19
In Brief
A Phase 3 clinical trial evaluating Remdesivir and Standard of Care for COVID-19. Completed, enrolled 4,891 participants across 183 sites in 15 countries.
Detailed Summary
The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesChina, France, Germany, Hong Kong, Italy, Japan, Netherlands, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedMar 2020
Enrollment StartMar 2020
Primary CompletionApr 2020
Study CompletionJun 2020
TodayJul 2026
First PostedMar 3, 2020
Enrollment StartMar 6, 2020
Primary CompletionApr 9, 2020
Study CompletionJun 30, 2020
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 6.3 years ago
Interventions
Remdesivirdrug
Administered as an intravenous infusion
Standard of Caredrug
Standard of Care Treatment for COVID-19 Infection